NCT00848640已完成2 期
Multi-center,Middle East, Phase-II Study, Non-comparative, of the RAF-Kinase Inhibitor Sorafenib in Patients With Advanced Renal Cell Carcinoma to Evaluate The Efficacy and Tolerability of the Drug
Egyptian Foundation For Cancer Research1 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2008年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 75
- 试验地点
- 1
- 主要终点
- evaluate the efficacy by evaluating the disease control rate (DCR) and safety of Sorafenib for first line patients unsuitable for another approved first line therapy with advanced RCC in the Middle East region.
研究概览
简要总结
The purpose study is to evaluate the efficacy and safety of Sorafenib as first line treatment for patients - unsuitable for another approved first line therapy - with advanced RCC in the Middle East Region.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient must provide written informed consent prior to receiving Sorafenib.
- •The male or female patient must be at least 18 years of age.
- •The patient must have pathologically proven advanced Renal Cell Carcinoma.
- •Only patients with measurable disease (According to RECIST) at baseline should be included in protocol where Disease Control Rate (DCR) is the primary endpoint.
- •The patient requires Sorafenib as First line therapy as the patient is unsuitable for another approved first line therapy for advanced RCC.
- •The patient must be, in the Investigator's opinion, reasonably likely to benefit from treatment with Sorafenib as a single agent.
- •The patient must have an Eastern Cooperative Oncology Group performance status of 0 -
- •The patient will not require other systemic anti-cancer chemotherapy, immunotherapy or hormonal therapy, except for bisphosphonates while taking Sorafenib.
- •Both male and female patients must use adequate barrier birth control methods during their participation in the protocol. The birth control methods must be used for 4 weeks for female patients and for 3 months for male patients after discontinuation of treatment with Sorafenib.
- •For patients, who have had major surgery, the wound must be completely healed prior to receiving Sorafenib treatment (4 weeks).
- •The patient must have within normal Renal & Hepatic function.
- •The patient must have within normal CBC.
排除标准
- •Patients who are currently enrolled in or have previously participated in any other Sorafenib trial.
- •Suitable or received any other systemic therapy for treatment RCC (IL-2, INF)
- •Patients who have a life expectancy of less than 2 months.
- •Patients with metastatic brain or meningeal tumours.
- •Patients are excluded who require any of the following:
- •Investigational drug therapy during the treatment with Sorafenib or within 30 days prior to their first dose of Sorafenib.
- •Concomitant Rifampicin.
- •Non-measurable disease according to RECIST.
- •Concomitant St. John's Wort (Hypericum perforatum).
- •Warfarin (or similar medication) is allowed.
- •Women who are pregnant or breast-feeding. Women of childbearing potential must have a negative pregnancy test performed within seven days of the start of study drug (please note that no laboratory data are collected in this study).
- •Patients with congestive heart failure greater than NYHA functional class II (symptomatic during ordinary activity)
- •Patients with cardiac arrhythmias greater than Grade 1 NCI CTCAE, Version 3.0 (conduction abnormality and supraventricular arrhythmia present but patient is asymptomatic; intervention not indicated, palpitations present and QTc > 0.45 - 0.47 second).
- •Patients with active coronary artery disease or ischemia.
- •Patients with Child-Pugh class C hepatic impairment.
- •Patients with severe renal impairment (calculated creatinine clearance of < 30 ml/min) or who require dialysis.
- •Patients with active uncontrolled hypertension.
- •Patients with recent or active bleeding diathesis.
- •Patients with any medical condition which could jeopardize their safety while taking an investigational drug.
研究组 & 干预措施
Sorafenib
Experimental
干预措施: Sorafenib (Drug)
结局指标
主要结局
evaluate the efficacy by evaluating the disease control rate (DCR) and safety of Sorafenib for first line patients unsuitable for another approved first line therapy with advanced RCC in the Middle East region.
时间窗: Disease Control Rate (DCR) defined as either CR, PR or SD for at least 8 weeks
次要结局
- Quality of life of patient with RCC and Progression Free Survival(One year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma PatientsThyroid CarcinomaNCT02114658Bayer18
终止
2 期
Sorafenib in Resected Non-small Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungNCT00532025Johannes Gutenberg University Mainz134
已完成
2 期
Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase InhibitorNon-Small Cell Lung CancerNCT00922584Chinese Society of Lung Cancer65
终止
1 期
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate CancerProstate CancerNCT00924807Beth Israel Medical Center4
终止
2 期
A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.Carcinoma, Renal CellNCT00678288Bayer16